Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR T Cells in Relapsed/Refractory Hairy Cell Leukemia
NCT04815356Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2022
- Primary completion
- Dec 2036
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of M971BBz in hairy cell leukemia (HCL) and Hairy cell leukemia variant (HCL-V) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Feasibility and Antitumor Effect. Started May 2022; status: recruiting.
02
Drugs
M971BBz
03
Conditions
hairy cell leukemia (HCL)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on NCT04815356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815356.